Table 2.

Main results of the studies reporting short- and long-term outcomes following in utero exposure to chemotherapy.

Study, Year	Type of Mother’s Cancer	Type of Systemic Treatments	Results
Hahn, 2006 [86]	Breast cancer	5′-fluorouracil, doxorubicin and cyclophosphamide	No stillbirths, miscarriages, or perinatal deaths 1 subarachnoid hemorrhage, 1 Down’s syndrome
Murthy, 2014 [41]	Breast cancer	5′-fluorouracil, doxorubicin and cyclophosphamide	No significant impairment of baby health at delivery and up to childhood 3 babies with congenital abnormalities
Amant, 2015 [87]	Breast cancer, hematological malignancies, cervical cancer, ovarian cancer, brain tumor, colon cancer, gastric cancer, renal cell cancer, tongue cancer, lung cancer, thyroid cancer, melanoma, sarcoma	Anthracycline-based, anthracycline plus taxane, CMF, taxane-based, platinum-agents, vinca alkaloid, dacarbazine, temozolomide, mitoxantrone	Comparison with control group (babies from healthy women without in utero exposure to chemotherapy): -Normal cognitive, cardiac and general development -Prematurity was correlated with worse cognitive outcome, irrespective of cancer treatment
Cardonick, 2015 [88]	Breast cancer, ovarian cancer, hematological malignancies	Anthracycline-based, anthracycline plus taxane, taxane-based	Comparison with control group (babies from women also diagnosed with a cancer during pregnancy, but without in utero exposure to chemotherapy): -Higher incidence of premature birth -No significant differences in cognitive development and behavioral competence
O’Laughlin, 2019 [43]	Breast cancer	Anthracycline plus taxane	Comparison with taxanes administration delayed to the postpartum period: -Normal neonatal development -No medical disorders

Abbreviations: CMF: Cyclophosphamide, methotrexate, 5′ fluorouracil.